Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience
about
Extensively drug-resistant tuberculosis: epidemiology and managementStructural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitorsRisk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigationMolecular epidemiology and clinical characteristics of drug-resistant Mycobacterium tuberculosis in a tuberculosis referral hospital in ChinaLoss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South AfricaCost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UKMap the gap: missing children with drug-resistant tuberculosisTreatment outcome of standardized regimen in patients with multidrug resistant tuberculosis.Comparative genomic analysis of Mycobacterium tuberculosis clinical isolates.The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership.Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimatesLonger hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan AfricaCost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in ChinaTransmission of Extensively Drug-Resistant Tuberculosis in South Africa.Reasons for Non-Enrollment in Treatment among Multi-Drug Resistant Tuberculosis Patients in Hunan Province, China.Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis.Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, ChinaEfficacy and effect of free treatment on multidrug-resistant tuberculosis.Factors associated with mortality in tuberculosis patients.Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method.Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.Antibacterial Effects of Liposomes Containing Phospholipid Cardiolipin and Fluoroquinolone Levofloxacin on Mycobacterium tuberculosis with Extensive Drug Resistance.Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis.Mortality and associated factors of patients with extensive drug-resistant tuberculosis: an emerging public health crisis in China.Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre RajkotTreatment Outcomes Associated with Multidrug-resistant TuberculosisDirect Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria
P2860
Q26830094-5557BAFE-3FDD-4498-A338-77DC9E10DADEQ27681391-714AAF42-AEC9-44A6-A371-9C313B4D8964Q28536653-59DAE04C-9F0F-42AB-B271-EE10BD8C8DF5Q28543698-C8A0BC0F-E5BB-41AD-892A-680E2613C833Q28544642-95A0B013-A316-4291-AD34-C5D2F29E76CEQ28544800-9AFBB995-1B58-4731-94C1-AE8925C611ABQ28547002-0651769B-2579-45ED-A9EF-F8CA5CE13047Q33561777-6BC8B77E-9565-4901-9B5E-5C1FA016960EQ33805218-8E61AC40-C8C5-4F4E-9DAB-8FA65AF25824Q33811760-24876213-D35D-4D0A-A666-929200507E4FQ33889335-1A812D4F-583B-4A23-89B1-1B5CB99DD5C5Q34467936-9A58C06E-B336-4487-B43B-487F7196CB0BQ36211805-E6FBF067-D360-401E-854E-AAD8A52C3DCAQ36252929-EAF7CFB1-3A85-4563-A4AA-919E2712D63CQ36257425-E8E4339C-4229-4442-BA03-CE4BC285F580Q36260334-7BB661C1-7305-4026-AED9-6FB01AE82443Q36825990-A89B3353-DE6F-47A2-B019-CBEE12230682Q37345726-099DEC93-0E7B-4528-AACE-43D17841E266Q38545953-13F89836-2845-40BA-9E28-02D257A360DCQ38621696-45128172-A386-4D6E-92B6-B71B1D118A24Q38644773-9D31006D-B943-4ED8-B12A-5C8FAD74A48EQ38718198-D7099282-9B8B-4FEA-888C-98A68C743536Q38867253-522548AF-9035-45A6-9C2C-F356A71240B0Q41376759-026CD8F9-128F-4996-9569-F87B23D05A5DQ42211847-A1F8512A-87CA-4594-BE97-AE288364E906Q47748869-E06616FF-62DF-4482-AFA3-CF79907C367BQ52594133-CF93CE43-78FA-4931-B9E5-18B6D3139462Q53041364-43444D04-F374-4282-A292-99980A13A253Q53172300-6F6FD020-8DEC-4770-A52A-77109707FAEBQ55208580-B143A0DB-3B83-4AB4-8726-3C869D50B72DQ55424020-9E2FEF67-3560-4C5D-8AC9-D0AF2A682865Q57488988-524E8BF6-08AE-4EEF-9860-8FE29CBA9A0FQ57922788-64F7EDB6-786F-4C7D-B510-BA06158FC6A5Q58750099-18C63213-DF13-4020-BF5F-108EDEA5A1EC
P2860
Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Characteristics and treatment ...... Beijing: a 13-year experience
@ast
Characteristics and treatment ...... Beijing: a 13-year experience
@en
Characteristics and treatment ...... Beijing: a 13-year experience
@nl
type
label
Characteristics and treatment ...... Beijing: a 13-year experience
@ast
Characteristics and treatment ...... Beijing: a 13-year experience
@en
Characteristics and treatment ...... Beijing: a 13-year experience
@nl
prefLabel
Characteristics and treatment ...... Beijing: a 13-year experience
@ast
Characteristics and treatment ...... Beijing: a 13-year experience
@en
Characteristics and treatment ...... Beijing: a 13-year experience
@nl
P2093
P2860
P921
P1433
P1476
Characteristics and treatment ...... Beijing: a 13-year experience
@en
P2093
P2860
P304
P356
10.1371/JOURNAL.PONE.0019399
P407
P577
2011-04-29T00:00:00Z